Clinical trial · Observational
Spectral CT in Radiotherapy for Cervical Cancer
The Clinical Research of Spectral CT in Radiotherapy for Cervical Cancer
NCT06433817CI-TRIAL-00077584recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study was to explore the potential application of spectral CT for radiotherapy in cervical cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervical Cancer | Malignant Cervical Neoplasm | CURATED_EXACT | 0.92 |
| Radiotherapy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Spectral computed tomography scan | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Comparison of spectral CT derived data with response evaluation in cervical cancer
- timeFrame
- through study completion, an average of 2 year
- description
- To evaluate the tumor response of using quantitative parameters in spectral CT for cervical cancer patients according to RECIST 1.1
Secondary outcomes (2)
- measure
- Identifying metastatic lymph nodes in cervical cancer with spectral CT
- timeFrame
- through study completion, an average of 2 year
- description
- To evaluate the diagnostic performances of using spectral CT for identifying metastatic lymph nodes in patients with cervical cancer
- measure
- Application of energy spectrum CT in brachytherapy of cervical cancer
- timeFrame
- through study completion, an average of 2 year
- description
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. All patients were confirmed cervical cancer by pathology 2. patients were treated with concurrent chemoradiotherapy 3. Spectral CT scans acquisition performed during the arterial phase and venous phase 4. All the patients underwent a 18F-FDG PET/CT before treatment Exclusion Criteria: 1. CT without spectral scans 2. History of allergy to intravenous contrast 3. Pregnant or potentially pregnant female subjects
References
Publications (0)
Data not yet available
No reference posted for this study.